PEG.CO

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$10M	+108.2%	$0.02	$0.02–$0.02	—	1
2027	$39M	+284.3%	$-0.02	$-0.02–$-0.02	—	1
2028	$97M	+148.2%	$0.00	$0.00–$0.00	—	0
2029	$170M	+74.9%	$0.00	$0.00–$0.00	—	0

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 2 of the last 2 reported quarters

Reported	Est. EPS	Actual	Surprise
2025-05-15	$-0.01	$-0.01	+0.0%
2024-11-15	$-0.01	$-0.01	+0.0%

DCF fair valuemodel estimate

Intrinsic value

$0.02

Price

$0.08

Implied downside

-77%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
PEG.COPharma Equity Group A/S	$0.08	+0.00%	$97M	—
BRAINP.COBrain+ A/S	$0.00	+0.00%	$5M	—
MONSO.COMonsenso A/S	$0.29	+14.17%	$19M	—
SMSMED.COScandinavian Medical Solutions A/S	$2.53	-4.53%	$70M	—
STENO.COStenocare A/S	$0.95

Pharma Equity Group A/S

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma that are in Phase II clinical trials. The company was incorporated in 2002 and is headquartered in Horsholm, Denmark.

www.pharmaequitygroup.com

Employees: 5
IPO / List date: May 16, 2023
HQ: DK

Held by traders on TradeandTell

No one on the platform currently holds PEG.CO.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in PEG.CO as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded PEG.CO yet.